Dactolisib Beats Rapamycin at Boosting Cancer Cell Death in Glioblastoma Models

Glioblastoma is an aggressive brain cancer that can survive treatment by activating alternative growth and survival signals. Researchers investigated whether blocking two connected signaling targets could make experimental drug combinations more effective at killing tumor cells. Their findings concern cancer treatment development, not evidence that these drugs extend lifespan or should be used for general health or prevention outside trials.

The study combined analyses of public tumor datasets and tissue samples with experiments in two established glioblastoma cell lines, cells derived from patients, and tumors grown on membranes surrounding chick embryos. Researchers compared dactolisib, which blocks PI3K and mTOR signaling, with rapamycin. They tested these drugs alongside experimental treatments targeting three other survival proteins, sometimes adding the chemotherapy drug azacitidine.

Tumor analyses supported increased activity in this survival pathway. AKT expression was significantly higher, while the increase in PIK3CA expression did not reach statistical significance. Patient-derived glioblastoma stem-like cells showed the highest expression of pathway components among models. Dactolisib combined with the other inhibitors and azacitidine reduced cell viability and increased programmed cell death more effectively than tested rapamycin combinations.

Dactolisib alone also slowed cell cycle progression. In the chick embryo tumor model, imaging showed reduced uptake of a radioactive glucose tracer. Molecular evidence of programmed cell death appeared only with the three survival protein inhibitors plus dactolisib. Together, these results suggest that broader pathway blockade could help overcome resistance, supporting additional laboratory research rather than immediate changes in care.

Important uncertainties remain. These were preclinical experiments, not a trial in patients, and the abstract provides no numerical effect sizes or detailed safety results. It does not establish whether effective drug concentrations can safely reach human brain tumors or improve survival. This summary is based on the abstract only; full methods, sample sizes, and detailed statistical analyses were not available.